人福医药：子公司取得药品注册证书

Group 1 - The core point of the article is that Renfu Pharmaceutical has received approval from the National Medical Products Administration for the drug registration certificate of Drospirenone and Ethinyl Estradiol Tablets [2] - In the fiscal year 2024, Renfu Pharmaceutical's revenue composition is as follows: pharmaceuticals account for 56.01%, pharmaceutical wholesale and related businesses account for 43.8%, and other businesses account for 0.19% [2]